Drug Name Mix-Ups Of Aricept/Azilect And Neulasta/Lunesta Under Investigation By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Confusion has occurred with oral and written orders, the Institute for Safe Medication Practices Medication Safety Alert reports.
You may also be interested in...
FDA Seeks To End Industry’s Use Of Error-Prone Medical Abbreviations
In partnership with PhRMA, FDA and the Institute for Safe Medication Practices have launched a campaign to prevent error-prone notation from appearing in labels and advertisements.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.